310 related articles for article (PubMed ID: 34347881)
1. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
Cleary Y; Gertz M; Grimsey P; Günther A; Heinig K; Ogungbenro K; Aarons L; Galetin A; Kletzl H
Clin Pharmacol Ther; 2021 Dec; 110(6):1547-1557. PubMed ID: 34347881
[TBL] [Abstract][Full Text] [Related]
2. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.
Cleary Y; Kletzl H; Grimsey P; Heinig K; Ogungbenro K; Silber Baumann HE; Frey N; Aarons L; Galetin A; Gertz M
Clin Pharmacokinet; 2023 Jun; 62(6):891-904. PubMed ID: 37148485
[TBL] [Abstract][Full Text] [Related]
3. In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.
Med Lett Drugs Ther; 2021 Jul; 63(1629):e1-e2. PubMed ID: 34544108
[No Abstract] [Full Text] [Related]
4. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB;
Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
[TBL] [Abstract][Full Text] [Related]
6. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
7. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
[TBL] [Abstract][Full Text] [Related]
8. [Risdiplam for the treatment of spinal muscular atrophy].
Vlodavets DV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
[TBL] [Abstract][Full Text] [Related]
9. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
10. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
11. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
Pineda ED; To TM; Dickendesher TL; Shapouri S; Iannaccone ST
Adv Ther; 2024 Jun; 41(6):2446-2459. PubMed ID: 38709394
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
[TBL] [Abstract][Full Text] [Related]
15. Risdiplam: A Review in Spinal Muscular Atrophy.
Paik J
CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
[TBL] [Abstract][Full Text] [Related]
16. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
18. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
19. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
[TBL] [Abstract][Full Text] [Related]
20. Risdiplam: First Approval.
Dhillon S
Drugs; 2020 Nov; 80(17):1853-1858. PubMed ID: 33044711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]